Nicolo Rigamonti

This person is no longer with EPFL

About
Privacy
Disclaimer

Graph Chatbot

Related publications (4)

Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy

Michele De Palma, Nicolo Rigamonti, Daniela Pais Ferreira, Alan Nicolas Thierry Guichard

Cancer immunotherapies are increasingly combined with targeted therapies to improve therapeutic outcomes. We show that combination of agonistic anti-CD40 with antiangiogenic antibodies targeting 2 proangiogenic factors, vascular endothelial growth factor A ...

2020

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

Michele De Palma, Ece Kadioglu, Nicolo Rigamonti, Antonino Cassarà, Céline Wyser Rmili, Damya Laoui

Pathological angiogenesis is a hallmark of cancer and a therapeutic target. Vascular endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2; also known as ANG2) are proangiogenic cytokines that sustain tumor angiogenesis and limit antitumor immunit ...

American Association for the Advancement of Science2017

Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade

Ioanna Keklikoglou, Michele De Palma, Ece Kadioglu, Nicolo Rigamonti, Céline Wyser Rmili

Angiopoietin-2 (ANG2/ANGPT2) is a context-dependent TIE2 receptor agonist/antagonist and proangiogenic factor. Although ANG2 neutralization improves tumor angiogenesis and growth inhibition by vascular endothelial growth factor (VEGF)-A signaling blockade, ...

Elsevier2014

A role for angiopoietin-2 in organ-specific metastasis

Michele De Palma, Nicolo Rigamonti

Angiopoietin-2 (ANG2/ANGPT2) has recently emerged as a promising target for the inhibition of tumor metastasis. In this issue of Cell Reports, Minami et al. show that the calcineurin-NFAT pathway promotes pulmonary tumor metastasis by inducing ANG2 in the ...

Elsevier2013

Page 1 of 1